Samuel R Saks - Net Worth and Insider Trading
Samuel R Saks Net Worth
The estimated net worth of Samuel R Saks is at least $0 dollars as of 2024-11-13. Samuel R Saks is the Director of Tonix Pharmaceuticals Holding Corp and owns about 0 shares of Tonix Pharmaceuticals Holding Corp (TNXP) stock worth over $0. Details can be seen in Samuel R Saks's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Samuel R Saks has not made any transactions after 2016-06-21 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Samuel R Saks
Samuel R Saks Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Samuel R Saks owns 4 companies in total, including Protagonist Therapeutics Inc (PTGX) , PDL BioPharma Inc (PDLI) , and Tonix Pharmaceuticals Holding Corp (TNXP) among others .
Click here to see the complete history of Samuel R Saks’s form 4 insider trades.
Insider Ownership Summary of Samuel R Saks
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| PTGX | Protagonist Therapeutics Inc | 2018-05-21 | Chief Development Officer |
| PDLI | PDL BioPharma Inc | 2019-06-20 | director |
| TNXP | Tonix Pharmaceuticals Holding Corp | 2016-06-21 | director |
 | | 2007-05-31 | director & Chief Executive Officer |
Samuel R Saks Latest Holdings Summary
Samuel R Saks currently owns a total of 1 stock. Samuel R Saks owns 0 shares of Tonix Pharmaceuticals Holding Corp (TNXP) as of June 21, 2016, with a value of $0.
Latest Holdings of Samuel R Saks
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| TNXP | Tonix Pharmaceuticals Holding Corp | 2016-06-21 | 0 | 0.15 | 0 |
Holding Weightings of Samuel R Saks
Samuel R Saks Form 4 Trading Tracker
According to the SEC Form 4 filings, Samuel R Saks has made a total of 0 transactions in Tonix Pharmaceuticals Holding Corp (TNXP) over the past 5 years. The most-recent trade in Tonix Pharmaceuticals Holding Corp is the acquisition of 0 shares on June 21, 2016, which cost Samuel R Saks around $50,000.
Insider Trading History of Samuel R Saks
- 1
Samuel R Saks Trading Performance
GuruFocus tracks the stock performance after each of Samuel R Saks's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Samuel R Saks is -49.33%. GuruFocus also compares Samuel R Saks's trading performance to market benchmark return within the same time period. The performance of stocks bought by Samuel R Saks within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Samuel R Saks's insider trading performs compared to the benchmark.
Performance of Samuel R Saks
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -9.43 | | | | | |
| Relative Return to S&P 500(%) | -11.49 | | | | | |
Samuel R Saks Ownership Network
Ownership Network List of Samuel R Saks
Ownership Network Relation of Samuel R Saks
Samuel R Saks Owned Company Details
What does Protagonist Therapeutics Inc do?
Who are the key executives at Protagonist Therapeutics Inc?
Samuel R Saks is the Chief Development Officer of Protagonist Therapeutics Inc. Other key executives at Protagonist Therapeutics Inc include Chief Financial Officer Asif Ali , director & President and CEO Patel Dinesh V Ph D , and Chief Development Officer Suneel Gupta .
Protagonist Therapeutics Inc (PTGX) Insider Trades Summary
Over the past 18 months, Samuel R Saks made no insider transaction in Protagonist Therapeutics Inc (PTGX). Other recent insider transactions involving Protagonist Therapeutics Inc (PTGX) include a net sale of 165,000 shares made by Patel Dinesh V Ph D , a net sale of 36,975 shares made by William D. Waddill , and a net sale of 39,624 shares made by Asif Ali .
In summary, during the past 3 months, insiders sold 22,203 shares of Protagonist Therapeutics Inc (PTGX) in total and bought 0 shares, with a net sale of 22,203 shares. During the past 18 months, 248,447 shares of Protagonist Therapeutics Inc (PTGX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 248,447 shares.
Protagonist Therapeutics Inc (PTGX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Protagonist Therapeutics Inc Insider Transactions
Samuel R Saks Mailing Address
Above is the net worth, insider trading, and ownership report for Samuel R Saks. You might contact Samuel R Saks via mailing address: 3180 Porter Drive, Palo Alto Ca 94304.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
